

Transparency Information

Leuven (Belgium) – January 9, 2013 – TiGenix NV (NYSE Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions (the Law) and the Royal Decree of February 14, 2008 regarding the publication of major holdings.

Following the capital increase dated December 27, 2012, the transparency data have changed as follows (status on December 31, 2012):

- **Information to be published in accordance with Article 15, §1, al. 1 of the Law**

Total of the registered capital:	EUR 10,028,858.60
Total number of securities conferring voting rights:	100,288,586
Total number of voting rights (denominator):	100,288,586

- **Information to be published in accordance with Article 15, §1, al. 2 of the Law**

The total number of rights (materialized or not in financial instruments) to subscribe to yet unissued financial instruments that are treated as securities conferring voting rights: 5,617,683 outstanding warrants that, in case they are all exercised, give rise to a total number of 5,617,683 voting rights.

TiGenix NV has not issued any other rights to subscribe to securities conferring voting rights or any securities without voting rights.

- **Information to be published in accordance with Article 18, §1 of the Law**

Each physical or legal person acquiring or transferring TiGenix' shares is required to notify the Belgian Financial Services and Markets Authority (FSMA) and TiGenix NV each time their shareholding crosses a threshold of three percent (3%) of the total number of voting securities (the denominator) (upwards or downwards). Such notification is also required when the threshold of five percent (5%) or a multiple of five percent (5%) is crossed.

Complete information regarding this requirement can be found in Article 14 of the articles of association of TiGenix NV.

Notifications must be submitted to both the FSMA and TiGenix NV.

To the FSMA:

- by e-mail: trp.fin@fsma.be, and
- a signed copy (for reasons of legal certainty) by fax: +32 2 220 59 12

TiGENIX

A copy of the notification must also be sent to TiGenix NV for the attention of Claudia D'Augusta, CFO:

- by e-mail: investor@tigenix.com, and
- a signed copy (for reasons of legal certainty) by fax: +32 16 39 79 70

For submitting the notifications, the FSMA recommends to use its standard form TR-1BE that is available on the FSMA website (<http://www.fsma.be/en/supervision/fm/gv/ah/circah/ov.aspx>) or can be requested by e-mail with TiGenix NV: investor@tigenix.com.

Detailed information regarding the transparency legislation can be found on the website of the FSMA.

For more information:

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one marketed product for cartilage repair, ChondroCelect[®], and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.